Value
9.0/10data confidence 33%| Component | Sub-score |
|---|---|
| Analyst target | 9.0 |
- ▸Attractively valued
ABCL · Why this verdict
Why AbCellera Biologics (ABCL) is rated SELL
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
VerdictSELL
Overall score5.3/10
ConfidenceMEDIUM
MacroNEUTRAL
TrendMatrix Research · core thesis
Engine thesis — one sentence
AbCellera is a cash-burning biotech with collapsing revenue and weak quality, offset by 40% analyst upside, modest insider buying and a reward-to-risk of 1.59.
Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.
Thesis pillars
| Pillar | Expectation | Trend |
|---|---|---|
Revenue is declining 90.6% YoY and operating margin is -567.2% with negative free cash flow, three of five value-trap signals. Bear case | Revenue should stabilize and decline less than 30% YoY over the next 12 months. | ↓Deteriorating |
| CounterA decline of this size from a pandemic-era base may be a normalization rather than ongoing deterioration, and pipeline milestones can reset revenue. | ||
Free cash flow is -70% of revenue and the Piotroski F-Score is 3/9, holding the quality score at 2.1 against a 4.0 floor. Quality breakdown | Cash burn should narrow to better than -40% of revenue. | →Stable |
| CounterThe current ratio component of 5 and a strong debt/equity score of 9.4 indicate the balance sheet can fund the burn for some time. | ||
The analyst target of $14.94 implies 21.7% upside from $12.27 against 13.7% downside (reward-to-risk 1.59), with analysts seeing 40% upside before haircut. Targets | Price should move toward the analyst target over 12 months. | Tripped↑Improving |
| CounterBinary biotech outcomes mean targets are unreliable and one clinical failure can erase the upside. | ||
Insiders made modest purchases of $1,545,680 (0.039% of market cap) and institutions are accumulating. Insider breakdown | Insiders should not shift into net selling over the next 12 months. | →Stable |
| CounterThe buying is only 0.039% of market cap, which is too small to establish strong conviction. | ||
The put/call ratio is 29.25, implied volatility is 108% and recent earnings are mixed with 2 beats and 2 misses. Risk breakdown | Put/call ratio should fall below 5 as sentiment improves. | ↓Deteriorating |
| CounterExtreme put/call readings in thin option markets can reflect hedging by a single holder rather than a broad bearish view. | ||
Revenue is declining 90.6% YoY and operating margin is -567.2% with negative free cash flow, three of five value-trap signals.
↓DeterioratingBear case
- Expectation
- Revenue should stabilize and decline less than 30% YoY over the next 12 months.
CounterA decline of this size from a pandemic-era base may be a normalization rather than ongoing deterioration, and pipeline milestones can reset revenue.
Free cash flow is -70% of revenue and the Piotroski F-Score is 3/9, holding the quality score at 2.1 against a 4.0 floor.
→StableQuality breakdown
- Expectation
- Cash burn should narrow to better than -40% of revenue.
CounterThe current ratio component of 5 and a strong debt/equity score of 9.4 indicate the balance sheet can fund the burn for some time.
The analyst target of $14.94 implies 21.7% upside from $12.27 against 13.7% downside (reward-to-risk 1.59), with analysts seeing 40% upside before haircut.
Tripped↑ImprovingTargets
- Expectation
- Price should move toward the analyst target over 12 months.
CounterBinary biotech outcomes mean targets are unreliable and one clinical failure can erase the upside.
Insiders made modest purchases of $1,545,680 (0.039% of market cap) and institutions are accumulating.
→StableInsider breakdown
- Expectation
- Insiders should not shift into net selling over the next 12 months.
CounterThe buying is only 0.039% of market cap, which is too small to establish strong conviction.
The put/call ratio is 29.25, implied volatility is 108% and recent earnings are mixed with 2 beats and 2 misses.
↓DeterioratingRisk breakdown
- Expectation
- Put/call ratio should fall below 5 as sentiment improves.
CounterExtreme put/call readings in thin option markets can reflect hedging by a single holder rather than a broad bearish view.
Per-dimension breakdown
Quality
2.1/10data confidence 86%| Component | Sub-score |
|---|---|
| ROE | 0.0 |
| ROA | 0.0 |
| Current ratio | 5.0 |
| FCF quality | 0.0 |
| Moat | 4.0 |
| Piotroski F | 3.3 |
- ▸Cash-burning: FCF -70% of revenue
- ▸No competitive moat
- ▸Weak Piotroski F-Score: 3/9
- ▸Quality concerns
Growth
5.0/10data confidence 50%Momentum
2.9/10data confidence 100%| Component | Sub-score |
|---|---|
| RSI | 5.5 |
| MACD | 1.7 |
| OBV | 1.7 |
| MA position | 4.0 |
| Volume | 1.4 |
- ▸Volume distribution (falling OBV)
- ▸Above 200-day MA
Sentiment
7.9/10data confidence 100%| Component | Sub-score |
|---|---|
| Analyst rating | 8.4 |
| Price target | 9.6 |
| erm sentiment | 5.0 |
- ▸Analyst upside: 54%
Insider
7.9/10data confidence 100%| Component | Sub-score |
|---|---|
| materiality | 6.5 |
| insider conviction | 8.0 |
| holder change | 10.0 |
| notable moves | 7.0 |
- ▸Modest insider buying — $1,545,680 (0.039% of mkt cap)
- ▸Institutions accumulating
Peer rank
2.2/10data confidence 80%| Component | Sub-score |
|---|---|
| value rank | 0.8 |
| quality rank | 3.3 |
| growth rank | 1.2 |
Technical
7.4/10data confidence 100%| Component | Sub-score |
|---|---|
| bollinger | 9.2 |
| support resistance | 8.7 |
| 52w position | 4.9 |
| gap | 7.0 |
Risk (lower is worse)
3.3/10data confidence 100%| Component | Sub-score |
|---|---|
| short interest | 3.9 |
| days to cover | 4.8 |
| volatility | 0.0 |
| put call | 0.0 |
| implied vol | 0.0 |
| beta | 4.7 |
| debt equity | 9.4 |
- ▸Elevated put/call: 3.35
- ▸High IV: 124%
Catalyst
5.8/10data confidence 100%| Component | Sub-score |
|---|---|
| erm | 5.0 |
| earnings history | 3.3 |
| earnings timing | 5.0 |
| surprise avg | 10.0 |
- ▸Earnings concerns: 2B/2M
- ▸Earnings in 4 days
How the verdict was assembled
Engine trigger
Quality below minimum threshold.
Engine technical detail
verdict_path:
L1:HARD_BLOCK:QUALITY_FLOORPassed (5)
- ASYMMETRY:2.2>=1.5
- INSIDER:OK
- NEWS_EVENTS:NONE_RECENT
- SEMI_CYCLE_PEAK:CLEAR
- MATERIALS_CYCLE_PEAK:CLEAR
Failed (2)
- MOMENTUM:2.9<4.5
- EARNINGS_PROXIMITY:4d<=7d
Warning (1)
- 8K_CSUITE_CHANGE:5.02 (officer departure/appointment)
Reward-to-Risk
2.25
Upside
+33.7%
Downside
15.0%
Sizing output
AVOID
Setup— — No clear chart pattern; technical signals are mixed
EdgeNo clear edge — No clear edge identified
SuitabilitySpeculative — Binary industry: Biotechnology
Investment implication
The SELL_IF_HOLDING verdict reflects the MOMENTUM gate's 2.9<4.5 outcome against Value at 9.0 and asymmetric R:R of 2.25.
The strongest dimensions are Value at 9.0, Sentiment at 7.9, and Insider at 7.9; the weakest are Quality at 2.1, Peer rank at 2.2, and Momentum at 2.9. The V9 engine flagged 2 failed gates with 1 warning, producing an asymmetric reward-to-risk of 2.25 and an engine sizing output of AVOID.
What would invalidate the thesis
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1Collapsing Revenue Value Trap
Trip ifRevenue decline exceeds 50% YoY in the next two quarters.
- P2Cash Burn Weak Quality
Trip ifFree cash flow falls below -100% of revenue.
- P3Analyst Upside Reward To RiskTripped
Trip ifPrice falls below the $11.41 stop level, more than 7% below current $12.27.
- P4Insider Buying And Institutional Accumulation
Trip ifInsider selling exceeds 0.1% of market cap in 90 days.
- P5Bearish Options And Mixed Earnings
Trip ifShort interest rises above 20% from current 12%.